Meeting
2012 Gastrointestinal Cancers Symposium
CD133 status influences in prognosis of patients with metastatic colorectal cancer receiving cetuximab.
Authors
Dai Inoue
Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
Dai Inoue , Satoshi Matsusaka , Noriko Yamamoto , Mitsukuni Suenaga , Yuji Mishima , Eiji Shinozaki , Yasuhito Terui , Nobuyuki Mizunuma , Yuichi Ishikawa , Kiyohiko Hatake
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 509)
DOI
10.1200/jco.2012.30.4_suppl.509
Abstract #
509
Poster Bd #
C32
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Liver and/or lung metastasectomy after cetuximab or bevacizumab+FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Sang-A Kim
Poster
2015 Gastrointestinal Cancers Symposium
Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.
First Author: Katrin Marie Sjoquist
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tissue factor: A link between metastatic colorectal cancer and thrombosis in patients in the CALGB (Alliance)/SWOG 80405 trial.
First Author: Sandra Algaze
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Delta radiomic parameters for the evaluation of liver metastases in patients with colorectal cancer treated with cetuximab rechallenge plus avelumab in the CAVE mCRC study.
First Author: Giulia Martini